01 July 2020 : Clinical Research
Clinical Characteristics and Prognosis of Young Patients with Coronary Heart Disease
Ruyi Zheng1BCF, Yan Liu1BDE, Zirui Hao2F, Huocheng Liao1BF*, Chun Xiao1BCFDOI: 10.12659/MSM.922957
Med Sci Monit 2020; 26:e922957
Table 2 Comparison between patients with and without clinical outcomes.
| Variables | With outcomes (n=64) | Without outcomes (n=908) |
|---|---|---|
| Age, years# | 45 (42–48) | 46 (43–49) |
| Male, n (%) | 60 (93.4%)* | 817 (90.0%) |
| Current Smoker, n (%) | 12 (19.3%) | 172 (18.9%) |
| Systolic blood pressure, mmHg | 129.4±17.5* | 123.6±16.1 |
| Diastolic blood pressure, mmHg | 76.7±11.3 | 77.9±12.5 |
| Heart rate, beats per minute | 78.4±11.6 | 73.3±10.6 |
| Alanine aminotransferase, U/L | 28.4±13.3 | 26.1±14.5 |
| Albumin, g/L | 39.6±3.5 | 38.5±3.0 |
| Total cholesterol, mmol/L | 4.88±1.15 | 4.70±1.06 |
| Triglyceride, mmol/L# | 1.56 (1.07–2.15) | 1.47 (1.02–2.11) |
| High density lipoprotein-cholesterol, mmol/L | 0.92±0.17 | 0.93±0.17 |
| Low density lipoprotein-cholesterol, mmol/L | 2.64±1.09 | 2.47±1.01 |
| Glycated hemoglobin A1c, % | 5.9±0.8 | 5.9±0.8 |
| eGFR, 1.73 m/mL/min | 94.5±10.7 | 95.3±11.2 |
| Hypertension, n (%) | 25 (38.3%)* | 308 (33.9%) |
| Diabetes mellitus, n (%) | 11 (16.7%)* | 130 (14.3%) |
| Dyslipidemia, n (%) | 3 (4.8%) | 40 (4.4%) |
| Family history of cardiovascular disease, n (%) | 29 (45.7%) | 401 (44.2%) |
| CHD classification | ||
| Stable angina, n (%) | 30 (47.3%) | 444 (48.9%)* |
| Unstable angina, n (%) | 32 (49.5%)* | 436 (48.0%) |
| Non-ST elevation myocardial infarction, n (%) | 1 (1.6%) | 10 (1.1%) |
| ST-elevation myocardial infarction, n (%) | 1 (1.6%) | 18 (2.0%) |
| Cardiac function (NYHA) | ||
| Class I, n (%) | 44 (68.4%) | 627 (69.1%) |
| Class II, n (%) | 16 (25.3%) | 234 (25.8%) |
| Class III, n (%) | 3 (4.6%) | 41 (4.5%) |
| Class IV, n (%) | 1 (1.6%) | 6 (0.6%) |
| Number of coronary arteries with stenosis | ||
| Single, n (%) | 19 (29.5%) | 273 (30.1%) |
| Double, n (%) | 16 (25.3%) | 225 (24.8%) |
| Triple, n (%) | 25 (39.7%) | 357 (39.3%) |
| Left main plus triple, n (%) | 4 (6.4%) | 53 (5.8%) |
| Left ventricular ejection fraction,% | 55.9±7.3 | 57.9±8.6 |
| Number of stents implantation# | 1 (0–2) | 1 (0–2) |
| Medications | ||
| Anti-hypertensive, n (%) | 10 (16.2%) | 154 (17.0%) |
| Anti-diabetic, n (%) | 5 (7.8%) | 74 (8.1%) |
| Anti-platelet, n (%) | 8 (12.8%) | 125 (13.8%) |
| Statins, n (%) | 7 (10.2%) | 99 (10.9%) |
| # Presented as median and interquartile range; * CHD – coronary heart disease; NYHA – New York Heart Association; eGFR – estimated glomerular filtration rate. | ||